Achillion Earnings Loss Stable $ACHN $XHS
Achillion Pharmaceuticals, Inc., a major Hepatitis C Drug provider, has announced its financial results for the first quarter FY-2015. The results shows Net Loss Stable $0.17 YoY, where as having $0 revenues the Cash, cash equivalents, marketable securities were $275.9 Million. View the full earnings release here.
Achillion Earnings Loss Stable $ACHN $XHS Read More »